Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage
Successes and Challenges Ahead: Navigating Changes in IRA and Medicare Part D
10/18/2024
Explore the implications of the CY 2025 Medicare Part D Redesign and the Inflation Reduction Act with AMCP Nexus 2024 session speakers, addressing successes and challenges faced by stakeholders as they prepare for significant changes ahead.
Explore the implications of the CY 2025 Medicare Part D Redesign and the Inflation Reduction Act with AMCP Nexus 2024 session speakers, addressing successes and challenges faced by stakeholders as they prepare for significant changes ahead.
Explore the implications of the...
10/18/2024
First Report Managed Care
Conference Coverage
State-Level Initiatives in Drug Pricing, PBM Reform, and Utilization Management
10/16/2024
Discover the latest state-level pharmacy policy trends, including pharmacy benefit manager (PBM) regulations and utilization management practices, from the eye-opening AMCP Nexus 2024 session.
Discover the latest state-level pharmacy policy trends, including pharmacy benefit manager (PBM) regulations and utilization management practices, from the eye-opening AMCP Nexus 2024 session.
Discover the latest state-level...
10/16/2024
First Report Managed Care
Conference Coverage
New Medicare Part D Out-of-Pocket Maximum Poses Barrier to Accessing Expensive Alzheimer Treatments
10/16/2024
A study presented at AMCP Nexus 2024 reveals that most patients with Alzheimer disease are not expected to reach the new Medicare Part D out-of-pocket maximum of $2000, potentially hindering access to high-cost treatments like lecanemab.
A study presented at AMCP Nexus 2024 reveals that most patients with Alzheimer disease are not expected to reach the new Medicare Part D out-of-pocket maximum of $2000, potentially hindering access to high-cost treatments like lecanemab.
A study presented at AMCP Nexus...
10/16/2024
First Report Managed Care
Conference Coverage
Cost-Effectiveness of MDMA-Assisted Therapy for PTSD
10/16/2024
Researchers at AMCP Nexus 2024 explored the cost-effectiveness of Midomafetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) in US health care settings, with findings suggesting it may be a more cost-effective...
Researchers at AMCP Nexus 2024 explored the cost-effectiveness of Midomafetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) in US health care settings, with findings suggesting it may be a more cost-effective...
Researchers at AMCP Nexus 2024...
10/16/2024
First Report Managed Care
Conference Coverage
Testing Artificial Intelligence Frameworks to Improve Managed Care for Rare Diseases
10/14/2024
Discover how artificial intelligence may alter mental health support for individuals with rare diseases, as presented at AMCP Nexus 2024, with key insights on the crucial role managed care professionals can play in filling the gap for...
Discover how artificial intelligence may alter mental health support for individuals with rare diseases, as presented at AMCP Nexus 2024, with key insights on the crucial role managed care professionals can play in filling the gap for...
Discover how artificial...
10/14/2024
First Report Managed Care
Conference Coverage
The Impact of Upfront Biomarker Testing on Total Cost of Care for Patients With aNSCLC and mCRC
10/14/2024
Multigene panel testing can increase eligibility for targeted therapy in lung and colorectal cancer patients while only representing a small portion of total care costs according to research presented at AMCP Nexus 2024.
Multigene panel testing can increase eligibility for targeted therapy in lung and colorectal cancer patients while only representing a small portion of total care costs according to research presented at AMCP Nexus 2024.
Multigene panel testing can...
10/14/2024
First Report Managed Care
Conference Coverage
Assessing the Effectiveness of DTBZ in Promoting Psychiatric Stability in Patients With Tardive Dyskinesia
10/14/2024
Research presented at AMCP Nexus 2024 examines the impact of deutetrabenazine (DTBZ) on psychiatric stability in patients with tardive dyskinesia, showing a potential improvement in schizophrenia-related hospitalizations and emergency...
Research presented at AMCP Nexus 2024 examines the impact of deutetrabenazine (DTBZ) on psychiatric stability in patients with tardive dyskinesia, showing a potential improvement in schizophrenia-related hospitalizations and emergency...
Research presented at AMCP Nexus...
10/14/2024
First Report Managed Care
Conference Coverage
Reviewing Newer Models, Current Role of Value-Based Contracts
10/17/2022
A panel of experts at AMCP Nexus 2022 provided insight on selecting and implementing value-based arrangements and the challenges that may arise.
A panel of experts at AMCP Nexus 2022 provided insight on selecting and implementing value-based arrangements and the challenges that may arise.
A panel of experts at AMCP Nexus...
10/17/2022
First Report Managed Care
Conference Coverage
Payer Challenges for Managing Drugs Granted Accelerated Approval by the FDA
10/14/2022
Speakers at AMCP Nexus 2022 reviewed how the accelerated approval pathway complicates payer decision-making, as well as some proposed reforms to alleviate issues related to data and costs.
Speakers at AMCP Nexus 2022 reviewed how the accelerated approval pathway complicates payer decision-making, as well as some proposed reforms to alleviate issues related to data and costs.
Speakers at AMCP Nexus 2022...
10/14/2022
First Report Managed Care
Conference Coverage
Upcoming Federal Legislative, Regulatory Updates
10/14/2022
The AMCP Policy and Government Relations team discusses the latest and upcoming federal legislative and regulatory updates regarding health policy at AMCP Nexus 2022.
The AMCP Policy and Government Relations team discusses the latest and upcoming federal legislative and regulatory updates regarding health policy at AMCP Nexus 2022.
The AMCP Policy and Government...
10/14/2022
First Report Managed Care
Conference Coverage
Significant Economic Burden, Direct Medical Costs Among OAs With RSV Infections
10/12/2022
Researchers estimated the annual economic burden of respiratory syncytial virus among adults aged 60 years and older in the United States.
Researchers estimated the annual economic burden of respiratory syncytial virus among adults aged 60 years and older in the United States.
Researchers estimated the annual...
10/12/2022
First Report Managed Care
Conference Coverage
Using Real-World Evidence to Analyze Economic, Clinical Benefit of Medication for Addiction Treatment
10/12/2022
Recent data shows members with opioid use disorder or overdose who use medication for addiction treatment may incur lower costs.
Recent data shows members with opioid use disorder or overdose who use medication for addiction treatment may incur lower costs.
Recent data shows members with...
10/12/2022
First Report Managed Care
Conference Coverage
HCRU, Costs by Treatment Modality for Patients With Newly Diagnosed Major Depressive Disorder
10/07/2022
“In this real-world sample of commercially insured patients, we observed variations in outcomes by treatment modality and an association between modality and disease severity,” said researchers at AMCP Nexus 2022.
“In this real-world sample of commercially insured patients, we observed variations in outcomes by treatment modality and an association between modality and disease severity,” said researchers at AMCP Nexus 2022.
“In this real-world sample of...
10/07/2022
First Report Managed Care
Conference Coverage
Digital Therapeutics: Assessing Payer Perception, Formulary Decision Trends
10/07/2022
“Coverage appears to be more likely for prescription-only digital therapeutics; however, challenges with proof of long-term benefit, patient adherence, and fulfillment remain,” said authors of a poster presented at AMCP Nexus 2022.
“Coverage appears to be more likely for prescription-only digital therapeutics; however, challenges with proof of long-term benefit, patient adherence, and fulfillment remain,” said authors of a poster presented at AMCP Nexus 2022.
“Coverage appears to be more...
10/07/2022
First Report Managed Care

Advertisement

Advertisement

Advertisement

Experts gather to discuss legislative and regulatory trends, new research findings, evolving strategies for a variety of conditions and treatments, and business trends to inform the future of managed care pharmacy. 

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement